3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
20
Lung Neoplasms
9
Small Cell Lung Carcinoma
6
Neoplasms
5
Carcinoma, Hepatocellular
5
Carcinoma
4
Urinary Bladder Neoplasms
3
Pancreatic Neoplasms
3
Neoplasms by Site
3
Neoplasm Metastasis
3
Endometrial Neoplasms
3
Cholangiocarcinoma
3
Neoplasms by Histologic Type
2
Liver Neoplasms
2
Gallbladder Neoplasms
2
Bile Duct Neoplasms
2
Vaccinia
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Resectable Intrahepatic Cholangiocarcinoma
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oropharyngeal Neoplasms
1
Non-Small Cell Lung Cancer Metastatic
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Interventions
Cisplatin
5
Gemcitabine
4
Oxaliplatin
2
Irinotecan
2
Fluorouracil
2
Capecitabine
2
Bevacizumab
2
zanidatamab
1
toripalimab
1
pembrolizumab
1
niraparib
1
neratinib
1
ivosidenib
1
futibatinib
1
fludarabine
1
envafolimab
1
encorafenib
1
durvalumab
1
binimetinib
1
Trastuzumab
1
Pemetrexed
1
Nivolumab
1
Folfox protocol
1
Docetaxel
1
Cyclophosphamide
1
Cetuximab
1
Carboplatin
1
Actigraphy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
durvalumab
×
30 days
×
Clear all
NCT03875235
2026-05-26
TOPAZ-1
AstraZeneca
Phase 3
Active not recruiting
810 enrolled
24 charts
1 FDA